Nabla Bio is a Boston-area biotech spun out of Harvard's Wyss Institute that combines generative AI with high-throughput wet-lab measurement to design antibodies and proteins from scratch. Its JAM (Joint Atomic Modeling) platform designs binders against historically undruggable multipass membrane proteins, including G protein-coupled receptors (GPCRs), ion channels, and transporters, which represent a large share of validated drug targets but resist conventional antibody discovery. The company pairs in-silico generative design with experimental high-throughput functional readouts to learn drug function directly, closing the design-build-test loop. Nabla has signed strategic collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda worth over $550M in potential upfront and milestone payments, validating its approach with multiple large pharma partners while continuing to build proprietary internal programs.